Clinical Trial Detail

NCT ID NCT02426125
Title A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

urethra transitional cell carcinoma

Therapies

Ramucirumab

Docetaxel

Age Groups: adult

No variant requirements are available.